Very promising for Giloblastoma patients.
Adding Tumor Treating Fields (TTFields) to maintenance temozolomide significantly prolongs both median and long-term survival.
Among patients with newly diagnosed glioblastoma multiforme, adding Tumor Treating Fields (TTFields) to maintenance temozolomide significantly prolongs both median and long-term survival, according to a study presented 21st Annual Scientific Meeting of the Society of Neuro-Oncology (SNO).
TTFields is a frequency-tuned, anti-mitotic, physical treatment modality delivered to the brain through a patient-operated, portable medical device called Optune. Results of a pre-specific successful interim analysis of the international, phase 3 trial (ClinicalTrials.gov Identifier: NCT00916409) comparing TTFields and temozolomide with temozolomide alone after radiotherapy and adjuvant temozolomide led to the approval of TTFields for the treatment of adult patients with glioblastoma.